AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12538197
Drug: Indomethacin 1
RxNorm normalized name: indomethacin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 1 mg (Group I, n=64)
Trial: 12538197
Drug: Indomethacin 2
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 2 mg (Group II, n=60)
Trial: 12538197
Drug: Methylprednisolone 80
RxNorm normalized name: methylPREDNISolone 80 mg/mL injectable suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 80 mg (Group III, n=82)
Trial: 10815751
Drug: Isradipine intravenous
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine intravenous infusion
Trial: 10815751
Drug: Isradipine oral
RxNorm normalized name: isradipine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine oral administration
Trial: 6496012
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg diazepam (4-5 min prior)
Trial: 6496012
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg diazepam (8-10 min prior)
Trial: 6496012
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg diazepam (4-5 min prior)
Trial: 6496012
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg diazepam (8-10 min prior)
Trial: 6496012
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg d-tubocurarine (4-5 min prior)
Trial: 6496012
Drug: Diazepam-pretreated groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam-pretreated groups (0.05 mg/kg and 0.1 mg/kg)
Trial: 29476763
Drug: Whole film-coated
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Whole film-coated bilayer tablets (reference)
Trial: 26607935
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS-PLs) 20 g/d, 118 kcal
Trial: 23464746
Drug: N2 O/O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2 O/O2 inhalation
Trial: 15947284
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine (ACh) infusion during hypoxia in HAPE-S subjects
Trial: 15947284
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of ACh infusion response with pulmonary artery systolic pressure in HAPE-S subjects
Trial: 12895199
Drug: Combination oral
RxNorm normalized name: PROBIOTIC COMBINATION ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oral contraceptive (40 microg ethinyloestradiol and 75 microg LNG)
Trial: 12895199
Drug: Combination oral
RxNorm normalized name: PROBIOTIC COMBINATION ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination oral contraceptive and LNG alone
Trial: 10480766
Drug: Insulin Dosage
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Dosage Guide
Trial: 10480766
Drug: Insulin Dosage
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Dosage Guide with rapid-acting insulin
Trial: 10480766
Drug: Insulin Dosage
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Dosage Guide with insulin pump
Trial: 31677711
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (40 mg/day)
Trial: 28195374
Drug: Weakly bent
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weakly bent molecules with peripheral core substitution
Trial: 28195374
Drug: Weakly bent
RxNorm normalized name: colonial bent grass pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weakly bent molecules with inside-directed fluorination
Trial: 25324332
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received eight cookies daily (11.5 g protein; 244 kcal) for 6 weeks.
Trial: 20569099
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg mifepristone administered 24 hours prior to sample collection
Trial: 20569099
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no mifepristone administered)
Trial: 17953377
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection analgesia (group V)
Trial: 12812355
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine (MQ) 15 mg/kg in a single oral dose
Trial: 15040558
Drug: Mefloquine-artesunate (MQ-AS)
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg daily for 3 days)
Trial: 15040558
Drug: Mefloquine-artesunate (MQ-AS)
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine-artesunate (MQ-AS) combination therapy
Trial: 14687445
Drug: Mirtazapine orally
RxNorm normalized name: Mirtazapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine orally disintegrating tablets (15-45 mg/day)
Trial: 10468082
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 0.02 U/kg/day for 6 months
Trial: 1972381
Drug: Estazolam 4
RxNorm normalized name: Estazolam
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estazolam 4 mg
Trial: 1972381
Drug: Estazolam 6
RxNorm normalized name: Estazolam
DrugBank: Estazolam (DB01215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estazolam 6 mg
Trial: 20619394
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) for 2 days preoperatively and 2 weeks postoperatively
Trial: 19596057
Drug: PXM generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXM generic formulation (LaborMed Pharma, Romania)
Trial: 17763612
Drug: OTC moisturizing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OTC moisturizing cream
Trial: 17763612
Drug: Sodium sulfacetamide
RxNorm normalized name: sodium sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium sulfacetamide 10% lotion
Trial: 17763612
Drug: Jar clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jar clindamycin 1%/benzoyl peroxide 5% gel
Trial: 17763612
Drug: Tube clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tube clindamycin 1%/benzoyl peroxide 5% gel
Trial: 15115516
Drug: Pulsed oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed oral terbinafine (standard dose)
Trial: 15115516
Drug: Pulsed oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed oral terbinafine (double dose)
Trial: 30862374
Drug: Dilutable quaternary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilutable quaternary ammonium agent
Trial: 25404551
Drug: Peritonsillar lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar lornoxicam (8 mg)
Trial: 19463127
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day (stable dose) (n=52)
Trial: 19463127
Drug: Atorvastatin titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin titration from 10 to 80 mg/day (n=50)
Trial: 19463127
Drug: Common therapy
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common therapy including lipid lowering drugs (n=46)
Trial: 17380211
Drug: Lumiracoxib (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib (100-400 mg once a day for chronic pain; 400 mg/day for acute pain)
Trial: 15262691
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% fluorouracil
Trial: 7612056
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride (4.4 mg as tablet, administered b.i.d. on days 4 to 10, single dose on days 1 and 11)
Trial: 7612056
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride (4.4 mg as tablet)
Trial: 2562605
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (50 micrograms/day)
Trial: 31637467
Drug: AquaCelle® fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AquaCelle® fish oil formulation (SEDDS)
Trial: 20657770
Drug: Treatment Interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Interruption (TI)
Trial: 20864621
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of eliglustat tartrate ≤ 20 mg/kg
Trial: 20864621
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of eliglustat tartrate ≤ 200 mg bid
Trial: 20864621
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses ≥ 10 mg/kg
Trial: 20864621
Drug: Single-dose pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose pharmacokinetics
Trial: 20864621
Drug: Multiple-dose pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose pharmacokinetics
Trial: 19282098
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone at 2.5 mg/day (n=4)
Trial: 19282098
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone at 5.0 mg/day (n=5)
Trial: 19282098
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone at 7.5 mg/day (n=5)
Trial: 19282098
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (all doses)
Trial: 17451575
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel implantation alone
Trial: 17451575
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel followed by laser/RF/IPL treatment
Trial: 10345151
Drug: Diet/exercise/supplement group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet/exercise/supplement group (n = 56)
Trial: 7988320
Drug: Sustacal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustacal administration
Trial: 31157819
Drug: CJR model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJR model (treatment)
Trial: 28061851
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPT) for malaria in schoolchildren (IPTsc)
Trial: 28061851
Drug: Training for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training for school staff to administer IPT
Trial: 28061851
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for health workers over teachers for drug administration
Trial: 28061851
Drug: Diagnosis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis of malaria infection before IPT administration
Trial: 23499604
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) influenza vaccine (Fluzone(®) Intradermal) 9μg HA per strain in 0.1mL
Trial: 23499604
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) influenza vaccine
Trial: 23499604
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) influenza vaccine (standard dose) 15μg HA per strain in 0.5mL
Trial: 23499604
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) influenza vaccine (standard dose)
Trial: 12149103
Drug: Enalapril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (mean dose 17 mg/day)
Trial: 12149103
Drug: Losartan (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (mean dose 77 mg/day)
Trial: 8083697
Drug: Vinorelbine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 100 mg/m2 orally
Trial: 8083697
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m2 intravenously (IV)
Trial: 2666482
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of ACETM
Trial: 2666482
Drug: Desensitization to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitization to ASA followed by rechallenge with 1000 mg of ACETM
Trial: 2666482
Drug: Desensitization to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitization to increasing doses of ACETM
Trial: 589351
Drug: Both Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Metformin and Chlorpropamide
Trial: 31733362
Drug: Higher priced
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher priced placebo cream
Trial: 31733362
Drug: Lower priced
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower priced placebo cream
Trial: 26360148
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) 1 ml at a concentration of 0.5%
Trial: 25399274
Drug: Warfarin (n=244;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (n=244; target INR 2-3)
Trial: 25399274
Drug: Warfarin (n=244)
RxNorm normalized name: (-)-Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (n=244)
Trial: 15764752
Drug: Third-generation agents
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation agents (e.g., gemcitabine, taxanes, vinorelbine)
Trial: 15764752
Drug: Platinum plus
RxNorm normalized name: Premier Value Multivital Platinum plus Lutein and Lycopene Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum plus a third-generation drug
Trial: 11996639
Drug: Trizivir (zidovudine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trizivir (zidovudine, lamivudine, abacavir), dosing schedule of one pill twice-daily
Trial: 25015354
Drug: 30 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg/d DHA
Trial: 25015354
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus daily multivitamin
Trial: 17516397
Drug: Imiquimod 7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 7.5% cream administered topically every other day for 20 days
Trial: 17516397
Drug: Intravenous meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous meglumine antimoniate administered at a dosage of 20 mg/kg per day every day for 20 days
Trial: 17516397
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with intravenous meglumine antimoniate and imiquimod 7.5% cream
Trial: 15366587
Drug: Osteocalcin capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteocalcin capsule
Trial: 11422018
Drug: Nadolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (40 mg)
Trial: 9722128
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg/day)
Trial: 9722128
Drug: Propanolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propanolol (20 mg/day and 40 mg during the menstrual period)
Trial: 9722128
Drug: Alprazolam (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.75 mg/day)
Trial: 9722128
Drug: Pyridoxine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (300 mg/day)
Trial: 7740595
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment condition (brief problem-oriented approach)
Trial: 3259170
Drug: Ketorolac tromethamine,
RxNorm normalized name: Ketorolac Tromethamine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine, 30 mg intramuscularly four times a day for 5 days
Trial: 3259170
Drug: Placebo, two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two capsules orally four times a day for the last 2 study days
Trial: 3259170
Drug: Aspirin, two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, two 325 mg capsules orally four times a day for the same schedule
Trial: 16724185
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone at 30 mg/day
Trial: 16724185
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of oral micronized progesterone (60 mg/day and 200 mg/day)
Trial: 12729080
Drug: 50% w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% w/v silver nitrate solution
Trial: 12729080
Drug: 25% w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% w/v silver nitrate solution
Trial: 12729080
Drug: 10% w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% w/v silver nitrate solution
Trial: 12729080
Drug: 2% w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% w/v silver nitrate solution
Trial: 12729080
Drug: 50% w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% w/v silver nitrate solution buffered to pH 6
Trial: 12729080
Drug: 50% w/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% w/v silver nitrate solution at pH 3.4, 4.2, 4.4, and 4.9
Trial: 10426831
Drug: High-dose sibrafiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Trial: 10426831
Drug: Low-dose sibrafiban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sibrafiban (dosage based on body weight and renal function, administered every 12 hours)
Trial: 10426831
Drug: Aspirin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (80 mg every 12 hours)
Trial: 10426831
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including aspirin and both doses of sibrafiban)
Trial: 6961944
Drug: Hypertransfusion (Hb:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertransfusion (Hb: 16-18 g/dl)
Trial: 6961944
Drug: Normotransfusion (Hb:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normotransfusion (Hb: 12-14 g/dl)
Trial: 31736460
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rapamycin (RET + RAP)
Trial: 31736460
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rapamycin without subsequent retrieval (NO RET + RAP)
Trial: 31253485
Drug: Estradiol ointment
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol ointment
Trial: 31253485
Drug: Testosterone ointment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone ointment
Trial: 31253485
Drug: Neutral base
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral base ointment
Trial: 25734980
Drug: Intravaginal prasterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal prasterone (6.5 mg daily for 12 weeks)
Trial: 21695210
Drug: PCV7 (2+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (2+1 doses)
Trial: 21695210
Drug: PCV7 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV7 (2 doses)
Trial: 19929217
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg for 3 months
Trial: 2957971
Drug: Aminohydroxybutylidene diphosphonate
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminohydroxybutylidene diphosphonate (2.5 mg/d intravenously for five days)